Aegis Capital Corp. acted as Exclusive Placement Agent on a $3.5 Million Public Offering for Clearmind Medicine Inc. (NASDAQ: CMND)
Clearmind Medicine Inc. (NASDAQ:CMND) has successfully completed a $3.5 million public offering, facilitated by Aegis Capital Corp. as the exclusive placement agent. The funds will support the company's mission to develop psychedelic-derived therapeutics targeting health issues like alcohol use disorder. Clearmind’s innovative approach is reinforced by a robust intellectual property portfolio, comprising 13 patent families, with plans for further acquisitions. The company aims to commercialize its psychedelic compounds as regulated medicines, foods, or supplements. This offering reflects Clearmind's commitment to advancing psychedelic medicine and building its research capabilities.
- Secured $3.5 million in public offering funding.
- Focus on the development of psychedelic-derived therapeutics for alcohol use disorder.
- Possesses a strong intellectual property portfolio with 13 patent families, indicating potential for growth and innovation.
- Plans to acquire additional patents to enhance product offerings.
- None.
NEW YORK, NY / ACCESSWIRE / April 10, 2023 / Aegis Capital Corp. acted as Exclusive Placement Agent on a
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The company's intellectual portfolio currently consists of 13 patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
For more information, please visit: https://www.clearmindmedicine.com
About Aegis Capital Corporation
Aegis Capital Corporation ("Aegis") has been in the wealth management and investment banking business since 1984. Aegis is dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Aegis also provides research and sales and trading services to institutional investors. Aegis offers its investment representatives a conflict free service platform and is able to provide a full-range of products and services including investment banking, wealth management, insurance, retirement planning, structured products, private equity, alternatives, equity research, fixed income and special purpose vehicles.
For more information about this offering or Investment Banking Services please email Banking@aegiscap.com or call (212) 813-1010.
Brokerage and investment advisory services are offered through Aegis Capital Corporation, a member of FINRA and SIPC. Investment and insurance products offered are not insured by the FDIC or any other federal government agency, are not deposits or other obligations of, or guaranteed by, a bank or any bank affiliate, and are subject to investment risks, including possible loss of the principal amount invested.
SOURCE: Aegis Capital Corp.
View source version on accesswire.com:
https://www.accesswire.com/748290/Aegis-Capital-Corp-acted-as-Exclusive-Placement-Agent-on-a-35-Million-Public-Offering-for-Clearmind-Medicine-Inc-NASDAQ-CMND
FAQ
What was the purpose of Clearmind Medicine Inc.'s recent public offering?
Who acted as the placement agent for Clearmind's public offering?
How many patent families does Clearmind Medicine Inc. currently hold?
What are Clearmind Medicine Inc.'s plans for its psychedelic compounds?
